ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2015
Emergence of fusarioses in a university hospital in Turkey during a 20-year period.
Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Diagnosis and management of invasive fungal infections due to non-Aspergillus moulds.The Journal of antimicrobial chemotherapy · 2025Review
- Comparison of molecular and MALDI-TOF MS identification and antifungal susceptibility of clinicalFrontiers in microbiology · 2022Article
- Study on the anti-biofilm mechanism of 1,8-cineole againstFrontiers in pharmacology · 2022Article
- Invasive Fusariosis in Nonneutropenic Patients, Spain, 2000-2015.Emerging infectious diseases · 2021Review
- Phylogenetic Analysis of Clinically Relevant Fusarium Species in Iran.Mycopathologia · 2020Article
- Detection ofJournal of fungi (Basel, Switzerland) · 2019Article
- Emerging Fungal Infections: New Patients, New Patterns, and New Pathogens.Journal of fungi (Basel, Switzerland) · 2019Review
- Infections Caused by Fusarium Species in Pediatric Cancer Patients and Review of Published Literature.Mycopathologia · 2018Review
- Biofilm Formation and Resistance to Fungicides in Clinically Relevant Members of the Fungal Genus Fusarium.Journal of fungi (Basel, Switzerland) · 2018Article
- Article
- South Indian Isolates of theFrontiers in microbiology · 2018Article
- Antifungal Susceptibility Testing of Fusarium: A Practical Approach.Journal of fungi (Basel, Switzerland) · 2017Review
- Global molecular epidemiology and genetic diversity of Fusarium, a significant emerging group of human opportunists from 1958 to 2015.Emerging microbes & infections · 2016Article
- Challenges in Fusarium, a Trans-Kingdom Pathogen.Mycopathologia · 2016Article
- Genotyping of Fusarium Isolates from Onychomycoses in Colombia: Detection of Two New Species Within the Fusarium solani Species Complex and In Vitro Antifungal Susceptibility Testing.Mycopathologia · 2016Article
- Diagnosis ofCurrent fungal infection reportsReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fusarium species have started appearing increasingly as the main cause of infections, particularly in immunocompromised patients. In this study, we aimed to present the first epidemiological data from Turkey, analyze fusariosis cases that have been monitored in a university hospital during the past 20 years, identify the responsible Fusarium species, and determine antifungal susceptibilities. A total of 47 cases of fusariosis was included in the study. Fusarium isolates were identified by multilocus sequence typing (MLST). Antifungal susceptibility was tested by the broth microdilution method according to the Clinical and Laboratory Standards Institute (CLSI) methodology. Of the Fusarium infections, 23.4 % were superficial, 44.7 % were locally invasive, and 31.9 % were disseminated. A significant increase was observed over the years. The Fusarium fujikuroi species complex (FFSC) proved to be the most frequent agent group (17 cases; 51.5 %), followed by the Fusarium solani species complex (FSSC) (14 cases; 42.4 %), the Fusarium dimerum species complex (FDSC), and the Fusarium oxysporum species complexes (FOSC) (one case each). Amphotericin B had the highest in vitro activity against all species. Voriconazole and posaconazole showed interspecies variability across and within Fusarium species complexes. In conclusion, our data support the fact that regional differences exist in the distribution of the Fusarium species and that species-specific differences are observed in antifungal susceptibility patterns. The monitoring of local epidemiological data by determining fungal identity and susceptibility are of importance in guiding the clinical follow-up of patients.
Indexed as
Identifiers
25994844What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.